Cite this post as:
Rory Spiegel. EMNerd – More on the FELLOW Trial. EMCrit Blog. Published on November 28, 2015. Accessed on October 2nd 2022. Available at [https://emcrit.org/emcrit/fellow-trial-methodology/ ].
Financial Disclosures:
Dr. Scott Weingart, Course Director, reports no relevant financial relationships with ineligible companies.
This episode’s speaker(s), (listed above), report no relevant financial relationships with ineligible companies.
CME Review
Original Release: November 28, 2015
Date of Most Recent Review: Jan 1, 2022
Termination Date: Jan 1, 2025
You finished the 'cast,
Now Join EMCrit!
As a member, you can...
- Get CME hours
- Get the On Deeper Reflection Podcast
- Support the show
- Write it off on your taxes or get reimbursed by your department
.
Get the EMCrit Newsletter
If you enjoyed this post, you will almost certainly enjoy our others. Subscribe to our email list to keep informed on all of the Resuscitation and Critical Care goodness.
This Post was by the EMCrit Crew, published 7 years ago. We never spam; we hate spammers! Spammers probably work for the Joint Commission.
Awesome stuff Rory! I think your summary really helps make clear that this trial doesn’t truly answer the question of whether apneic oxygenation really works or not. It’s hard to frame it as one that does, given that only 30% of patients were truly apneic. I’d like to see a trial that truly randomizes ApOx vs none, with a standard method of PreOx for all comers. What sample size would be needed? Until then, it makes sense to keep on with an intervention that makes a lot of physiological sense with no known harms, no appreciable cost, and one that’s… Read more »
Love the critical thinking and breakdown of the trial – thanks for the time and effort. I am concerned that the loss of power due to nonparametric hypothesis testing is a bit overstated. Nonparametric tests are, by nature, more conservative – given our fear of type I error, this is a benefit. As you said, it comes at the cost of decreasing power. However, that decrease in power is not constant; usually for trials greater than 100 participants, the decreased power is negligible. Especially since all results were non-significant, I would not consider the choice of appropriate statistical test a… Read more »
HI William, Thank you so much for the kind words. I think your points on non-parametric testing are entirely valid. My intention of the post was to discuss the fact that this trial was incapable of differentiating a clinically important difference from statistical chance. Choosing a continuous variable of questionable clinical significance as their primary outcome, likely was far more of a factor in why the study was underpowered than their use of a non-parametric analysis but I thought it was important to discuss both factors in the analysis. To your second point, from my perspective the goal of apneic… Read more »
The unpinning philosophy of the P value is that the null hypothesis is correct. Therefore, I think that your opening statement is incorrect. This is explained in 1 and 2. It is also tempting to look for absolute differences that are non-significant then explain that the study is underpowered. The reader is then left with the impression that had the study been bigger then the differences would become significant. This is also incorrect and explained in 3. 1. Goodman SN. Towards evidence based medical statistics. The P value fallacy. Ann Intern Med 1999;130:995-1004. 2. Sedgwick P. Understanding P values. BMJ… Read more »
Hi Richard, Thank you so much for your response. While I completely agree with your statement, “the unpinning philosophy of the p-value is that the null hypothesis is true”, I don’t think a failure to reject the null hypothesis proves the null hypothesis. Rather it states the data was unable to demonstrate a difference. Goodman discusses this misconception in (1). Yes I agree any retrospective power analysis in a negative trial will invariably demonstrate an underpowered trial. Rather using a confidence interval approach to determine whether a trial is capable of differentiating a clinically important outcome from statistical chance is… Read more »